Spots Global Cancer Trial Database for Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

Official Title: Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

Study ID: NCT04402840

Conditions

Acute Respiratory Distress Syndrome

COVID-19

Interventions

Stellate Ganglion Block

Study Description

Brief Summary: The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.

Detailed Description: Primary Aim: • To determine safety of stellate ganglion block (SGB) in ARDS Secondary Aim: * To determine efficacy of SGB in slowing the progression of ARDS